Alector, Inc. (NASDAQ:ALEC) Given Consensus Rating of "Hold" by Brokerages

Key Points

• Alector, Inc. has received an average recommendation of "Hold" from analysts, with a price target of $4.17 among brokers in the last year.
• The stock is currently trading at $1.45, down 2.7%, with a market capitalization of approximately $144.99 million.
• Institutional investors hold 85.83% of Alector's stock, with recent notable acquisitions increasing positions significantly.

Shares of Alector, Inc. (NASDAQ:ALEC - Get Free Report) have earned an average recommendation of "Hold" from the seven research firms that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $4.1667.

A number of equities analysts recently issued reports on ALEC shares. HC Wainwright increased their price target on shares of Alector from $7.00 to $10.00 and gave the stock a "buy" rating in a research note on Friday, May 9th. Mizuho raised Alector from a "neutral" rating to an "outperform" rating and increased their price target for the company from $2.50 to $3.50 in a report on Monday, July 28th.

Alector Trading Up 1.0%

Alector stock traded up $0.02 during trading hours on Friday, reaching $1.45. The stock had a trading volume of 393,973 shares, compared to its average volume of 728,281. Alector has a 52 week low of $0.87 and a 52 week high of $6.37. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.34 and a quick ratio of 3.34. The company has a fifty day simple moving average of $1.54 and a 200-day simple moving average of $1.43. The stock has a market cap of $144.49 million, a PE ratio of -1.15 and a beta of 0.86.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Acadian Asset Management LLC increased its position in shares of Alector by 50.7% during the second quarter. Acadian Asset Management LLC now owns 2,170,388 shares of the company's stock worth $3,033,000 after purchasing an additional 729,727 shares in the last quarter. Los Angeles Capital Management LLC increased its holdings in shares of Alector by 5.3% during the second quarter. Los Angeles Capital Management LLC now owns 151,896 shares of the company's stock valued at $213,000 after acquiring an additional 7,600 shares in the last quarter. Bank of Montreal Can acquired a new position in shares of Alector during the second quarter valued at about $73,000. FNY Investment Advisers LLC grew its position in Alector by 100.0% during the 2nd quarter. FNY Investment Advisers LLC now owns 20,000 shares of the company's stock worth $28,000 after purchasing an additional 10,000 shares during the last quarter. Finally, TD Asset Management Inc increased its stake in Alector by 483.3% during the 2nd quarter. TD Asset Management Inc now owns 651,738 shares of the company's stock valued at $912,000 after purchasing an additional 540,000 shares in the last quarter. Institutional investors own 85.83% of the company's stock.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.